Genelabs Technologies, Inc. Provides Update on Hepatitis C Drug Development with Collaboration Partners

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB) announced today that based on progress to date, its hepatitis C drug development and commercialization collaboration with Novartis is continuing to the next phase.